Tarextumab: Updated Phase Ib/II data

Updated data from 27 patients with SCLC in the dose-escalation Phase Ib portion of the international Phase Ib/II PINNACLE trial showed that

Read the full 226 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE